NCT04318002View on ClinicalTrials.gov

Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

August 27, 2023

Study Completion Date

August 27, 2023

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

RH5.1/Matrix-M

3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)

Trial Locations (1)

Unknown

Ifakara Health Institute Clinical Trial Facility, Bagamoyo

All Listed Sponsors
collaborator

Ifakara Health Institute

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

University of Oxford

OTHER

NCT04318002 - Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania | Biotech Hunter | Biotech Hunter